CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type
- PMID: 19073834
- DOI: 10.1177/0891988708327810
CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type
Abstract
We exploratively measured APPs alpha, a secreted fragment of the non-amyloidogenic cleavage of amyloid precursor protein via a-secretase, and tau protein phosphorylated at threonine 181 (p tau) in the cerebrospinal fluid of 10 patients with mild cognitive impairment, 20 patients with dementia of Alzheimer's type, and 10 controls. Cerebrospinal fluid APPs alpha and p tau levels were correlated with cognitive performance. P tau levels were significantly elevated in mild cognitive impairment and in patients with dementia of Alzheimer's type, APPs alpha levels were significantly reduced in patients with dementia of Alzheimer's type compared to the controls. APPs alpha levels were associated with Mini Mental State Examination total scores but not with Delayed Verbal Recall Test performance. Vice versa, pt au levels correlated only with Delayed Verbal Recall Test in patients with dementia of Alzheimer's type or mild cognitive impairment. Both, an increase in p tau levels and a decrease in cerebrospinal fluid APPs alpha, seem to refer to relevant but functionally different processes in the development of mild cognitive impairment and dementia of Alzheimer's type.
Similar articles
-
CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71. Neurology. 2009. PMID: 19307538
-
Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.Neurobiol Aging. 2006 Feb;27(2):237-44. doi: 10.1016/j.neurobiolaging.2005.01.011. Epub 2005 Apr 7. Neurobiol Aging. 2006. PMID: 16399209
-
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.J Neurol Sci. 2006 Dec 21;251(1-2):124-8. doi: 10.1016/j.jns.2006.09.014. Epub 2006 Nov 9. J Neurol Sci. 2006. PMID: 17097109
-
[Diagnosing the mild cognitive impairment stage of Alzheimer's disease].Seishin Shinkeigaku Zasshi. 2004;106(3):269-80. Seishin Shinkeigaku Zasshi. 2004. PMID: 15164576 Review. Japanese.
-
CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?Int J Geriatr Psychiatry. 2003 May;18(5):407-11. doi: 10.1002/gps.845. Int J Geriatr Psychiatry. 2003. PMID: 12766916 Review.
Cited by
-
MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10).J Biol Chem. 2013 May 10;288(19):13748-61. doi: 10.1074/jbc.M112.381392. Epub 2013 Apr 1. J Biol Chem. 2013. PMID: 23546882 Free PMC article.
-
Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.J Biol Chem. 2010 May 21;285(21):15753-60. doi: 10.1074/jbc.M110.110742. Epub 2010 Mar 26. J Biol Chem. 2010. PMID: 20348102 Free PMC article.
-
Regulation of α-secretase ADAM10 expression and activity.Exp Brain Res. 2012 Apr;217(3-4):343-52. doi: 10.1007/s00221-011-2885-7. Epub 2011 Oct 4. Exp Brain Res. 2012. PMID: 21969210 Review.
-
Comparative analysis of single and combined APP/APLP knockouts reveals reduced spine density in APP-KO mice that is prevented by APPsα expression.Acta Neuropathol Commun. 2014 Mar 31;2:36. doi: 10.1186/2051-5960-2-36. Acta Neuropathol Commun. 2014. PMID: 24684730 Free PMC article.
-
The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein.J Biol Chem. 2010 Jul 2;285(27):20664-74. doi: 10.1074/jbc.M109.055608. Epub 2010 Apr 28. J Biol Chem. 2010. PMID: 20427278 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical